Iron polymaltose

MECHANISM OF ACTION 

Iron polymaltose supplied iron required for the synthesis of hemoglobin, myoglobin, and various iron-containing enzymes. After the iron became available to the body, it was transported to tissues and used mainly for red blood cell production and oxygen transport. In individuals with iron deficiency, replacement of the deficient iron supported hemoglobin formation and helped restore normal erythropoiesis.

PHARMACOKINETICS 

Absorption

Iron polymaltose was absorbed mainly from the small intestine, particularly the duodenum and jejunum. The extent of absorption was influenced by the body's iron requirement and existing iron stores. Absorption increased when iron stores were depleted and generally decreased when sufficient iron was available.

Distribution

The apparent volume of distribution for intravenous iron carbohydrate complexes like iron polymaltose typically approximates 3 Liters, which corresponds closely to the total plasma volume of an adult human. 

Metabolism

Iron was not metabolized in the usual drug-metabolism pathway. Instead, absorbed iron was incorporated into biologically important substances, including hemoglobin, myoglobin, and iron-dependent enzymes, or deposited in storage forms such as ferritin and hemosiderin. Iron released during the normal breakdown of aged red blood cells was recycled and reused for the formation of new hemoglobin.

Elimination

Iron was not eliminated primarily through the kidneys because the body conserved and reused most of the absorbed iron. Small quantities were lost naturally through feces, urine, sweat, skin shedding, and other physiological routes. Because iron was efficiently retained and recycled, excessive iron administration could lead to accumulation in the body.

PHARMACODYNAMICS 

Iron polymaltose provided iron needed for the formation of hemoglobin, myoglobin, and other iron-dependent enzymes. The iron was gradually released from the iron–polymaltose complex and became available for red blood cell formation and replenishment of depleted iron stores. Increased iron availability supported erythropoiesis and helped restore the blood’s oxygen-carrying capacity. The complex released iron in a controlled manner, thereby limiting the amount of unbound iron available at one time.

ADMINISTRATION 

Iron polymaltose was given either orally or by injection, depending on the available formulation and the patient's clinical needs. Oral preparations were taken at the prescribed dose and could be taken with food when gastrointestinal discomfort occurred. Injectable preparations were administered by trained healthcare professionals through the appropriate intravenous or intramuscular route. Parenteral administration was used when oral iron was not effective, was poorly tolerated, or could not be used.

DOSAGE AND STRENGTH 

The dose of iron polymaltose varied according to the extent of iron deficiency, age, body weight, hemoglobin level, and formulation used. Oral preparations were supplied in different strengths, usually based on their elemental iron content. For injectable preparations, the dose was determined according to the individual iron requirement and the strength of the particular product. Treatment was maintained long enough to correct the deficiency and restore iron reserves.

DRUG INTERACTIONS 

Iron polymaltose could interact with medicines or substances that altered iron absorption or were affected by iron in the digestive tract. Oral iron could decrease the absorption of certain medicines, including some antibiotics and thyroid hormone preparations, when administered together. Antacids, calcium-containing products, and other substances could also reduce the absorption of oral iron. These absorption-related interactions were generally not applicable to injectable iron polymaltose, although combining it with other injectable iron products was usually avoided unless specifically required.

FOOD INTERACTIONS 

Iron polymaltose was generally not greatly influenced by food and could be taken with or after meals. Taking it with food could help reduce gastrointestinal discomfort. However, foods and drinks containing calcium, phytates, or polyphenols, including tea and coffee, could interfere with iron absorption. When better absorption was needed, these items were preferably taken separately from the iron dose.

CONTRAINDICATIONS 

Iron polymaltose was contraindicated in individuals who had a known allergy to iron polymaltose or any ingredient in the formulation. It was also avoided in patients with iron-overload conditions such as hemochromatosis or hemosiderosis and in anemia that was not related to iron deficiency. Caution was required when the body could not properly utilize iron or when treatment could lead to excessive iron accumulation.

SIDE EFFECTS 

Iron polymaltose was associated mainly with mild, temporary adverse effects. These included: 

• Nausea.

• Vomiting.

• Abdominal discomfort.

• Constipation.

• Diarrhea.

• Headache.

• Dizziness.

• Changes in stool color.

• Injection-site reactions.

• Skin discoloration.

• Hypersensitivity reactions.

OVER DOSE 

Excessive intake of iron polymaltose could cause iron poisoning and excessive iron accumulation. Initial symptoms could include nausea, vomiting, abdominal pain, diarrhea, and gastrointestinal irritation. Severe overdose could cause metabolic disturbances, cardiovascular problems, liver injury, and damage to other organs. Treatment depended on the severity of the overdose and required prompt medical evaluation and supportive care.

TOXICITY 

Iron polymaltose generally showed good tolerability when used at appropriate doses. Toxicity mainly occurred when excessive amounts of iron were administered or accumulated in the body. Severe toxicity could result in gastrointestinal injury, metabolic abnormalities, liver damage, circulatory disturbances, and, in serious cases, multiple-organ dysfunction. Appropriate dosing and monitoring were therefore important, particularly during repeated or high-dose treatment.